ALT/AST ratio can be used as a simple and effective noninvasive biomarker to identify individuals with high risk of NAFLD, which is helpful for the early detection of this prevalent liver disease. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.